A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice (NCT07055607) | Clinical Trial Compass
By InvitationNot Applicable
A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice
Spain, Switzerland, United Kingdom1,250 participantsStarted 2025-05-01
Plain-language summary
This observational study will explore how Wegovy® (Semaglutide) is used in everyday situations, how it might affect things like weight, body mass index (BMI) and waist circumference, and what kind of impact it could have on overall quality of life. The overall purpose of this study is to understand how Wegovy impacts weight when used as part of regular medical care. Participants will be treated with Wegovy as prescribed to the participant by their doctor, in accordance with normal clinical practice. The study will last for about two years.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria:
* Signed consent obtained before any study-related activities (study-related activities are any pro-cedure related to recording of data according to the protocol).
* Are eligible for Wegovy and are due to initiate treatment for the first time within the study period; the decision to initiate treatment with commercially available Wegovy has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
* Male or female, age above or equal to 18 years at time of signing informed consent.
* Have at least one reported weight measurement documented at baseline or within 28 days prior to baseline.
* Participants must be able to complete the electronic patient reported outcome (ePRO) questionnaires on a compatible electronic device with internet access.
* Fulfil the respective reimbursement criteria in the visit prior to / at baseline in Switzerland and United Kingdom (UK).
Exclusion criteria:
* Previous participation in this study. Participation is defined as having given informed consent in this study.
* Presence of a documented refusal or unwillingness to participate in research.
* Previous treatment with other obesity management pharmacotherapy or any glucagon like pep-tide-1 (GLP- 1) receptor agonist up to 90 days prior to baseline in Switzerland and UK.
* Previous treatment with other obesity management pharmacotherapy or any GLP- 1 receptor agon…
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Since this is an observational study that's enrolling by invitation only, can you tell me if I would even be considered for it, and how patients are typically selected to participate?
2Because this study is observational rather than a traditional interventional trial, does that mean I would just be receiving Wegovy as part of my normal care while being monitored, rather than being assigned to an experimental treatment?
3The study is tracking real-world weight changes over two years — how does that timeline compare to what I might expect if I simply started Wegovy outside of a study, and is there any added benefit to me personally from being part of this research?
4Since this trial is focused on how Wegovy performs in everyday clinical practice rather than a controlled setting, what does that tell us about what's already known — and not yet fully understood — about its long-term safety and effectiveness for someone in my situation?
5Are there standard obesity treatment options I should consider first, and how would you weigh those against the possibility of participating in this two-year observational study?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Absolute change in body weight (kilograms [kg])
Timeframe: From baseline (0 months) to the end of observation (24 months)
2
Percentage change in body weight (percentage [%])
Timeframe: From baseline (0 months) to the end of observation (24 months)